Hypothetical cost savings associated with “observation” for low-risk prostate cancer

A newly published article in JAMA Oncology has reported hypothetical costs savings to Medicare of $320 million over a 3-year time frame if men of > 70 years with low-risk prostate cancer are simply “observed” as opposed being given immediate treated. … READ MORE …